SCHEMBL16633394

SCHEMBL16633394

CN(C)C(=O)C(c1ccc(OC(F)(F)F)cc1)N(C(=O)O)C(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.38
BCHE P06276 1/20 0.37
ACHE P22303 1/20 0.37
LIPE Q05469 1/20 0.37
EPHX2 P34913 1/20 0.37
PDE2A O00408 6/20 0.37
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
TRPV1 Q8NER1 1/20 0.36
NR1H2 P55055 1/20 0.36
NR1H3 Q13133 1/20 0.36
EPHX1 P07099 1/20 0.35
SERPINE1 P05121 1/20 0.35
PPARG P37231 1/20 0.35
PPARD Q03181 1/20 0.35
PPARA Q07869 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16633285 0.89 ALDH1A1 (0.36) ALDH1A1BCHEACHELIPEEPHX2
SCHEMBL16633233 0.85 EPHX1 (0.43) ALDH1A1EPHX2PDE2ASLC6A2SLC6A4
SCHEMBL16633449 0.83 ALDH1A1 (0.39) ALDH1A1EPHX2PDE2AEPHX1SERPINE1
SCHEMBL16633661 0.81 EPHX2 (0.40) ALDH1A1EPHX2PDE2APPARGPPARD
SCHEMBL16633428 0.79 ALDH1A1 (0.38) ALDH1A1BCHEACHELIPEEPHX2
SCHEMBL16563726 0.78 TRPV1 (0.40) ALDH1A1EPHX2PDE2ATRPV1EPHX1
SCHEMBL16633204 0.78 MMP2 (0.40) ALDH1A1BCHEACHELIPEPDE2A
SCHEMBL16633980 0.77 ALDH1A1 (0.41) ALDH1A1EPHX2PDE2ATRPV1EPHX1
SCHEMBL16633417 0.76 ALDH1A1 (0.38) ALDH1A1EPHX2PDE2ATRPV1EPHX1
SCHEMBL16634078 0.76 EPHX1 (0.40) ALDH1A1EPHX2PDE2ASLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9469637-B2 Nitrogenated heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-10-18 US disclosed
US-20150105373-A1 NITROGENATED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105373-A1 NITROGENATED HETEROCYCLIC COMPOUND PDE2A, PDE5A, PDE3A ALDH1A1 492/4885BCHE 198/4885ACHE 24/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.